Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy

Journal of Infectious Diseases

Volumn 182, Issue 3, 2000, Pages 758-765

  Condra, Jon H ^a   Petropoulos, Christos J ^b   Ziermann, Rainer ^b   Schleif, William A ^a   Shivaprakash, Malathi ^a   Emini, Emilio A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR;

AMINO ACID SUBSTITUTION; ARTICLE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; PREDICTION; PRIORITY JOURNAL; VIRUS RESISTANCE;

CARBAMATES; DRUG RESISTANCE, MICROBIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; NELFINAVIR; PHENOTYPE; PROTEIN BINDING; RITONAVIR; SAQUINAVIR; SULFONAMIDES;

EID: 0033827608     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315782     Document Type: Article

References (37)

1. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure
2. Virologic failure during combination therapy with Crixivan and RT inhibitors is often associated with expression of resistance-associated mutations in RT only
3. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
4. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
5. Pharmacokinetics of L-735,524, an HIV protease inhibitor
6. 3
7. Pharmacokinetics and tolerability studies of L-735,524, a new HIV protease inhibitor
8. Genetic correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure
9. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type-1
10. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy
11. SC-52151, a novel inhibitor of the human immunodeficiency virus protease
12. Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151
13. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus
14. Protease inhibitors in patients with HIV disease: Clinically important pharmacokinetic considerations
15. The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors
16. A comparison of bid and tid dosing of nelfinavir when given in combination with stavudine (d4T) and lamivudine (3TC) for up to 48 weeks
17. Pilot study of bid and tid combinations of saquinavir-sgc (S), delavirdine (D), zidovudine (ZDV) and lamivudine (3TC) as initial therapy: Pharmacokinetic (PK) interaction between S-SGC and D
18. HIV protease inhibitors, saquinavir, indinavir, and ritonavir: Inhibition of CYP3A4-mediated metabolism of testosterone and binzoxazinorifamycin, KRM-1645, in human liver microsomes
19. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
20. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
21. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs
22. HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833
23. The addition of a second protease inhibitor eliminates amprenavir-efavirenz drug interactions and increases plasma amprenavir concentrations
24. Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV) and ritonavir (RTV) combinations in healthy volunteers
25. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
26. Virological and clinical implications of resistance to HIV-I protease inhibitors
27. Resistance during early virological rebound on amprenavir plus zidovudine plus lamivudine triple therapy or amprenavir monotherapy in ACTG protocol 347
28. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
29. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
30. Efficacy of indinavir (IDV)/ritonavir (RTV)-based regimens (IRBR) among patients with prior protease inhibitor failure
31. Salvage therapy with twice daily indinavir (Crixivan) 800 mg plus ritonavir (Norvir) 200 mg based regimen in clinical practice
32. Pharmacological considerations in antiretroviraI therapy
33. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers